ReviewFrontiers in endocrinology2026
Case Report: A case of x-linked hypophosphatemic rickets complicated with polyostotic fibrous dysplasia caused by PHEX gene mutation and literature review.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a rare case of a 60-year-old male patient with X-linked hypophosphatemic rickets (XLH) caused by a PHEX gene mutation complicated with polyostotic fibrous dysplasia (FD). The patient presented with bilateral lower limb deformity for 59 years and recurrent fractures for 30 years. Physical examination revealed short stature (113 cm), multiple skeletal deformities, and limited joint mobility. Laboratory investigations showed persistent hypophosphatemia (0.43 mmol/L), elevated alkaline phosphatase (262 U/L), and increased urinary phosphorus excretion. Imaging studies demonstrated both typical features of XLH, including brush-like changes at the metaphysis of long bones and bowing deformity of the lower limbs, as well as characteristic findings of FD such as "ground-glass" appearance in the skull and femur. Genetic analysis identified a missense mutation NM_000444.6:c.1946G>T (p.Gly649Val) in the PHEX gene, which was classified as "Likely Pathogenic" according to ACMG guidelines. The patient was treated with oral phosphate preparations combined with calcitriol, resulting in gradual normalization of serum phosphorus levels and significant relief of bone pain symptoms. To our knowledge, this represents the first reported case of PHEX gene mutation-associated XLH combined with polyostotic FD. This case enriches the clinical phenotype spectrum of rare bone disorders and highlights the importance of comprehensive evaluation for patients presenting with hypophosphatemia and complex skeletal abnormalities. Clinicians should consider the possibility of concurrent hereditary phosphate metabolic disorders and bone dysplasias, and integrate clinical manifestations, imaging findings, and multi-gene testing for accurate diagnosis and individualized management. Further studies are needed to elucidate the underlying mechanism of this unique combination of two distinct genetic bone disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.